Nasdaq

Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved

About Attention Deficit/Hyperactivity Disorder (ADHD)ADHD is a chronic neurobiological and developmental disorder that affects millions of children and often continues into adulthood. The condition is ...
Seeking Alpha

Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved

KANSAS CITY, Kan., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (CING) (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform ...
Business Insider

Cingulate Inc’s Strong Financial Position and Promising ADHD Drug Development Prospects Garner Buy Rating from Maxim Group

Maxim Group analyst Naz Rahman maintained a Buy rating on Cingulate Inc (CING – Research Report) yesterday and set a price target of $2.00. Naz Rahman of Maxim Group has given a Buy rating to ...
Nasdaq

Cingulate Inc. Provides Clinical Update on CTx-1301 Pre-NDA Meeting and Announces $3 Million Grant for CTx-2103 Development

Cingulate Inc. completes FDA Pre-NDA meeting for ADHD drug CTx-1301 and secures $3 million grant for anxiety treatment CTx-2103. Cingulate Inc. announced the successful completion of a Pre-NDA meeting ...
Morningstar

Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone) | Morningstar

KANSAS CITY, Kan., April 09, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform ...
The Business Journals

Cingulate wins $3M from private foundation to help develop third time-release drug

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Cingulate will use the money ...
Seeking Alpha

Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved

In-Person FDA Meeting Scheduled for April 2; New Drug Application Submission Targeted for Mid-2025 $17.5 million increase in Working Capital; Cash Runway Extending into Q4, Well Beyond Target Date for ...